Efstathios Kastritis, MD, is an Associate Professor at the National and Kapodistrian University of Athens, Athens, Greece.
Dr Kastritis obtained his medical degree from the University of Athens, Athens, Greece, in 1997 followed by his residency in internal medicine at the Alexandra Hospital, University of Athens School of Medicine, Athens, Greece, qualifying in 2006. Dr Kastritis worked in the Oncology and Hematology Department at the University of Athens, School of Medicine, Athens, Greece between 2006 and 2008 and was also a researcher at the Jerome Lipper Multiple Myeloma Center, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, until 2010. Dr Kastritis was Assistant Professor of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, until 2016.
Dr Kastritis currently serves on the Scientific Advisory Committee of the International Waldenström’s Macroglobulinemia Foundation (IWMF).
Speaking on plasma cell disorders and novel therapeutics
Dr Kastritis focuses on developing new diagnostic and therapeutic techniques for multiple myeloma, Waldenström’s macroglobulinemia and amyloidosis, with several recent publications on the diagnosis and management of cardiac amyloidosis. Recently, he has also co-authored multiple papers on COVID-19, namely a paper regarding neutralizing antibody response post-COVID-19 vaccination in myeloma.